{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:39:29Z","timestamp":1769600369478,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Sharp & Dome Corp, Madrid, Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s12325-017-0600-1","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T06:49:01Z","timestamp":1502693341000},"page":"2104-2119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain"],"prefix":"10.1007","volume":"34","author":[{"given":"Rafael","family":"C\u00e1mara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irmina","family":"Gozalbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Arag\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"issue":"6","key":"600_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/QCO.0b013e328358b000","volume":"25","author":"L Pagano","year":"2012","unstructured":"Pagano L, Caira M. Risks for infection in patients with myelodysplasia and acute leukemia. Curr Opin Infect Dis. 2012;25(6):612\u20138.","journal-title":"Curr Opin Infect Dis"},{"key":"600_CR2","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2146\/ajhp080325","volume":"66","author":"J Menzin","year":"2009","unstructured":"Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009;66:1711\u20137.","journal-title":"Am J Health Syst Pharm"},{"issue":"14 Suppl 13","key":"600_CR3","first-page":"9","volume":"18","author":"KA Marr","year":"2004","unstructured":"Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Williston Park). 2004;18(14 Suppl 13):9\u201314.","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"600_CR4","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/ijms13010774","volume":"13","author":"MT Montagna","year":"2012","unstructured":"Montagna MT, De Giglio O, Napoli C, Lovero G, Caggiano G, Delia M, et al. Invasive fungal infections in patients with hematologic malignancies (aurora project): lights and shadows during 18-months surveillance. Int J Mol Sci. 2012;13(1):774\u201387.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"600_CR5","first-page":"1068","volume":"91","author":"L Pagano","year":"2006","unstructured":"Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068\u201375.","journal-title":"Haematologica"},{"issue":"8","key":"600_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/1469-0691.12002","volume":"19","author":"M Nucci","year":"2013","unstructured":"Nucci M, Garnica M, Gloria AB, Lehugeur DS, Dias VC, Palma LC, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukemia or myelodysplasia in Brazil. Clin Microbiol Infect. 2013;19(8):745\u201351.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"600_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1086\/428780","volume":"191","author":"DP Kontoyiannis","year":"2005","unstructured":"Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350\u201360.","journal-title":"J Infect Dis"},{"issue":"1","key":"600_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1046\/j.1365-2141.2000.02312.x","volume":"111","author":"C Girmenia","year":"2000","unstructured":"Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol. 2000;111(1):272\u20136.","journal-title":"Br J Haematol"},{"key":"600_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.leukres.2014.01.007","volume":"38","author":"C Girmenia","year":"2014","unstructured":"Girmenia C, Micozzi A, Piciocchi A, et al. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. Leuk Res. 2014;38:469\u201374.","journal-title":"Leuk Res"},{"issue":"31","key":"600_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10096-011-1397-5","volume":"2012","author":"M Michallet","year":"2012","unstructured":"Michallet M, B\u00e9net T, Sobh M, et al. Invasive Aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis. 2012;2012(31):991\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"600_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3324\/haematol.2010.030825","volume":"96","author":"C Even","year":"2010","unstructured":"Even C, Bastuji-Garin S, Hicheri Y, et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived to fungal disease. A case-control study. Haematologica. 2010;96:337\u201341.","journal-title":"Haematologica"},{"key":"600_CR12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1086\/591531","volume":"15","author":"L Slobbe","year":"2008","unstructured":"Slobbe L, Polinder S, Doorduijn JK, et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis. 2008;15:1507\u201312.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"600_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3324\/haematol.2011.051995","volume":"97","author":"MR Ananda-Rajah","year":"2012","unstructured":"Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA. Comparative clinical effectiveness of prophylactic voriconazole\/posaconazole to fluconazole\/itraconazole in patients with acute myeloid leukemia\/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012;97(3):459\u201363.","journal-title":"Haematologica"},{"issue":"Suppl 6","key":"600_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12464","volume":"20","author":"L Pagano","year":"2014","unstructured":"Pagano L, Caira M. The role of primary antifungal prophylaxis in patients with haematological malignancies. Clin Microbiol Infect. 2014;20(Suppl 6):19\u201326.","journal-title":"Clin Microbiol Infect"},{"key":"600_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348\u201359.","journal-title":"N Engl J Med"},{"issue":"4","key":"600_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JH, Bennett JE. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360.","journal-title":"Clin Infect Dis"},{"key":"600_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bmt.2010.175","volume":"46","author":"J Maertens","year":"2011","unstructured":"Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update. Bone Marrow Transplant. 2011;46:709\u201318.","journal-title":"Bone Marrow Transplant"},{"key":"600_CR18","unstructured":"National Comprehensive Cancer Network. Prevention and treatment of cancer-related infection. NCCN version 2.2017. NCCN Clinical Practice Guidelines in Oncology [serial on the Internet]. v.2. 2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf ."},{"key":"600_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2334-12-83","volume":"12","author":"S Grau","year":"2012","unstructured":"Grau S, de la C\u00e1mara R, Sabater FJ, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain. BMC Infect Dis. 2012;12:83.","journal-title":"BMC Infect Dis"},{"key":"600_CR20","unstructured":"Merck & Co. Inc. Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck, 2014."},{"key":"600_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40265-015-0348-3","volume":"75","author":"K McKeage","year":"2015","unstructured":"McKeage K. Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections. Drugs. 2015;75:397\u2013406.","journal-title":"Drugs"},{"key":"600_CR22","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/jac\/dkv380","volume":"71","author":"OA Cornely","year":"2016","unstructured":"Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71:718\u201326.","journal-title":"J Antimicrob Chemother"},{"key":"600_CR23","unstructured":"INE. Mortality tables for the Spanish population by year, sex, age and functions. Instituto Nacional de Estad\u00edstica. 2013. www.ine.es . Accessed: October 2015."},{"key":"600_CR24","unstructured":"Howlader N, Krapcho M, Garshell J et al. SEER cancer statistics review, 1975\u20132011. Bethesda: National Cancer Institute 2013. http:\/\/seer.cancer.gov\/archive\/csr\/1975_2011\/ . Accessed: October, 2015."},{"key":"600_CR25","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"600_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","volume":"11","author":"J L\u00f3pez-Bastida","year":"2010","unstructured":"L\u00f3pez-Bastida J, Oliva J, Anto\u00f1anzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11:513\u201320.","journal-title":"Eur J Health Econ"},{"key":"600_CR27","unstructured":"Pharmacists Official College [Consejo General de Colegios Oficiales de Farmac\u00e9uticos]. https:\/\/botplusweb.portalfarma.com\/ . Accessed October 2015."},{"key":"600_CR28","unstructured":"SmPC Posaconazole [Ficha t\u00e9cnica Posaconazol. Centro de Informaci\u00f3n online de Medicamentos (CIMA) de la Agencia Espa\u00f1ola de Medicamentos y productos Sanitarios (AEMPS)]. http:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do?metodo=buscar . Accessed October 2015."},{"key":"600_CR29","unstructured":"SmPC Fluconazole [Ficha t\u00e9cnica Fluconazol. Centro de Informaci\u00f3n online de Medicamentos (CIMA) de la Agencia Espa\u00f1ola de Medicamentos y productos Sanitarios (AEMPS)]. http:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do?metodo=buscar . Accessed October 2015."},{"key":"600_CR30","unstructured":"SmPC Itraconazole [Ficha t\u00e9cnica Itraconazol. Centro de Informaci\u00f3n online de Medicamentos (CIMA) de la Agencia Espa\u00f1ola de Medicamentos y productos Sanitarios (AEMPS)]. http:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do?metodo=buscar . Accessed: October, 2015."},{"key":"600_CR31","unstructured":"CCEMG-EPPI-Centre Cost Converter. http:\/\/eppi.ioe.ac.uk\/costconversion\/default.aspx . Accessed October 2015."},{"key":"600_CR32","unstructured":"National Cancer Institute. SEER cancer statistics review 1975\u20132003. Age-adjusted SEER incidence and US death rates and 5-year relative survival rates. 2006. http:\/\/seer.cancer.gov\/archive\/csr\/1975_2003\/ . Accessed October 2015."},{"key":"600_CR33","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/cncr.21699","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodisplastic syndrome. Cancer. 2006;106:1099\u2013109.","journal-title":"Cancer"},{"key":"600_CR34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3111\/13696998.2012.761633","volume":"16","author":"G Papadopoulos","year":"2013","unstructured":"Papadopoulos G, Hunt S, Prasad M. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study. J Med Econ. 2013;16:374\u201380.","journal-title":"J Med Econ"},{"issue":"4","key":"600_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","volume":"16","author":"JA Sacrist\u00e1n","year":"2002","unstructured":"Sacrist\u00e1n JA, Oliva J, Llano J, et al. What is an efficient health technology in Spain? Gac Sanit. 2002;16(4):334\u201343.","journal-title":"Gac Sanit"},{"key":"600_CR36","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","volume":"98","author":"ST Witte de","year":"2001","unstructured":"de Witte ST, Suciu G, Verhoef B, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood. 2001;98:2326\u201331.","journal-title":"Blood"},{"key":"600_CR37","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute Myeloid Leukemia: results of the medical research council AML15 Trial. J Clin Oncol. 2013;31:3360\u20138.","journal-title":"J Clin Oncol"},{"key":"600_CR38","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1524-4733.2008.00486.x","volume":"12","author":"AK O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan AK, Pandya A, Papadopoulos G, et al. Cost-Effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health. 2009;12:666\u201373.","journal-title":"Value Health"},{"key":"600_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3111\/13696998.2014.1000460","volume":"18","author":"AH Sung","year":"2015","unstructured":"Sung AH, Marcella SW, Xie Y. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States. Med Econ. 2015;18:341\u20138.","journal-title":"Med Econ"},{"key":"600_CR40","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.clinthera.2015.06.014","volume":"37","author":"SY Cho","year":"2015","unstructured":"Cho SY, Lee DG, Choi JK. Cost\u2013benefit analysis of posaconazole versus fluconazole or itraconazole as a primary antifungal prophylaxis in high-risk hematologic patients: a propensity score-matched analysis. Clin Ther. 2015;37:2019\u201327.","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"600_CR41","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.jval.2011.05.032","volume":"14","author":"K Rely","year":"2011","unstructured":"Rely K, Alexandre PK, Escudero GS. Cost effectiveness of posaconazole versus fluconazole\/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico. Value Health. 2011;14(Suppl 1):S39\u201342.","journal-title":"Value Health"},{"key":"600_CR42","doi-asserted-by":"publisher","first-page":"e0140930","DOI":"10.1371\/journal.pone.0140930","volume":"10","author":"M Fung","year":"2015","unstructured":"Fung M, Kim J, Martin FM, et al. Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia. PLoS ONE. 2015;10:e0140930.","journal-title":"PLoS ONE"},{"key":"600_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3111\/13696998.2013.781028","volume":"16","author":"K Athanasakis","year":"2013","unstructured":"Athanasakis K, Petrakis I, Kyriopoulos J. Posaconazole vs fluconazole\/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece. J Med Econ. 2013;16:678\u201384.","journal-title":"J Med Econ"},{"key":"600_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1600-0609.2008.01141.x","volume":"81","author":"WB Stam","year":"2008","unstructured":"Stam WB, O\u2019Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol. 2008;81:467\u201374.","journal-title":"Eur J Haematol"},{"key":"600_CR45","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00520-010-1022-7","volume":"19","author":"G Dranitsaris","year":"2011","unstructured":"Dranitsaris G, Khoury H. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. Support Care Cancer. 2011;19:1807\u201313.","journal-title":"Support Care Cancer"},{"key":"600_CR46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/jac\/dkp507","volume":"65","author":"C Hahn-Ast","year":"2010","unstructured":"Hahn-Ast C, Glasmacher A, M\u00fcckter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother. 2010;65:761\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"600_CR47","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3324\/haematol.2011.053058","volume":"97","author":"C Girmenia","year":"2012","unstructured":"Girmenia C, Frustaci AM, Gentile G, et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica. 2012;97:560\u20137.","journal-title":"Haematologica"},{"key":"600_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0924-8579(08)70016-5","volume":"32","author":"M Cuenca-Estrella","year":"2008","unstructured":"Cuenca-Estrella M, Bernal-Martinez L, Buitrago MJ, et al. Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicrob Agents. 2008;32:143\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"600_CR49","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/jac\/dkq121","volume":"65","author":"JJ Vehreschild","year":"2010","unstructured":"Vehreschild JJ, R\u00fcping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukemia (AML): a 6\u00a0year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65:1466\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"600_CR50","doi-asserted-by":"crossref","unstructured":"Zhao YJ, Khoo AL, Tan G et al. Fluconazole, itraconazole, posaconazole and voriconazole in invasive fungal infection prophylaxis: network meta-analysis and pharmacoeconomic evaluation. In Antimicrob Agents Chemother 2015.","DOI":"10.1128\/AAC.01985-15"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0600-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T10:58:07Z","timestamp":1570013887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0600-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0600-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]},"assertion":[{"value":"2 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}